Skip to main content

Table 2 Third Generation CD20 monoclonal antibodies

From: Novel CD20 monoclonal antibodies for lymphoma therapy

Monoclonal Ab

Ig type

Patients

Regimen

Overall responserate

Adverse events

Reference

Obinutuzumab (GA-101)

IgG1

21

Obinutuzumab (Refractory B cell NHL) 1600/800 mg 400/400 mg

60% 35%

Infusion related reaction, neutropenia, anemia, thrombocytopenia, tumor lysis syndrome

[49]

28

G-CHOP (Relapsed or refractory FL) 1600/800 mg 400/400 mg

94%

Infusion related reaction, neutropenia, neuropathy, infection

[50]

28

G-FC (Relapsed or refractory FL) 1600/800 mg 400/400 mg

93%

Infusion related reaction, neutropenia, rash, infection

[50]

PRO131921

IgG1

24

PRO131921 (Relapsed/refractory B cell NHL) 25 to 800 mg/m2

27%

Infusion related reaction, upper respiratory tract infection, neutropenia

[51]

Ocaratuzumab (AME-133v)

IgG1

56

Ocaratuzumab (Relapsed/Refractory FL) 100 mg/m2 375mg/m2

36%

Infusion related reaction, nasopharyngitis, asthenia, lymphopenia, infection

[48]